Legislation / Legal

NICE: The National Institute for Health and Clinical Excellence (NICE) has responded to last week’s court ruling concerning NICE’s judgement on when certain drugs for the treatment of Alzheimer’s disease can best be prescribed.
 
Commenting on last week’s ruling, NICE Chief Executive, Andrew Dillon said:
“We were challenged on six grounds, and the court found in our favour on five of them.  This ruling strengthens NICE by endorsing our approach to evaluating drugs.  Our guidance stands and the drugs continue to be recommended only for people with moderate Alzheimer’s disease, but the court has asked us to clarify our guidance when it is used for certain groups.
Press release ~ NICE’s appraisal of drugs for Alzheimer’s disease ~ Dementia: Supporting people with dementia and their carers in health and social care ~ Improving services and support for people with dementia ~ Dementia: International Comparisons ~ Identifying Alternatives to Hospital for People with Dementia - Lincolnshire Case Study ~ Alzheimer's Society
Free, Secure, Compliant UK Public Sector IT Recycling Service